Hospitals, pharmacies and nonprofit organizations are often driven by compassion when donating medications, equipment or medical supplies to mission organizations or healthcare partners overseas. While these contributions can support global health efforts and save lives, good intentions alone do not guarantee safe or effective outcomes.
Differences in regulatory requirements, clinical standards, storage conditions and local infrastructure can introduce legal, safety and ethical risks. Without careful planning and due diligence, donations may unintentionally harm patients, violate regulations, strain recipient organizations or create reputational exposure for donors. International medical giving should be approached with the same level of rigor and risk awareness applied to patient care at home.
U.S. FDA Considerations for Medication Donations
The U.S. Food and Drug Administration (FDA) does not authorize the export of expired medications for patient use, even for humanitarian purposes. The agency also discourages donations of small quantities of nonexpired medications, noting that sorting and redistribution can be inefficient and costly for relief organizations.
FDA guidance emphasizes that appropriate drug donations should:
- Be provided in large, cost‑effective quantities
- Include assurances of safety, effectiveness and product quality
- Avoid donations from individuals or small groups, which are often destroyed
Limited Emergency Exceptions
In rare, case‑by‑case emergencies, the FDA may allow the donation of expired medications if the receiving country requests and accepts them, product quality is evaluated, and sufficient evidence supports safety and effectiveness. Even in these circumstances, the FDA consistently notes that financial contributions are often the most effective way to support international relief efforts.
International Standards for Responsible Donations
The World Health Organization’s (WHO) Guidelines for Medicine Donations outline principles designed to protect patients and strengthen recipient health systems. Key expectations include:
- Donations must be based on an expressed need and agreed-upon quantities
- Products should be approved for use in the recipient country and align with national essential medicines lists or WHO model lists
- Drug formulation, strength, labeling and packaging should match local clinical practice
- Products must come from quality‑assured sources and meet standards in both donor and recipient countries
- Returned medications, patient‑issued supplies and free samples should never be donated
- Products should have at least one year of remaining shelf life upon arrival
- Labels must be clearly understood by local healthcare professionals and include essential information such as the generic name, batch number, dosage, manufacturer, storage conditions and expiration date
- Packaging and shipment should follow international standards, with detailed packing lists and manageable carton weights
- Donors should plan jointly with recipients and cover transport, customs, storage and disposal costs unless otherwise agreed
Many countries impose additional national requirements. In Ghana, for example:
- Donations must meet an expressed national need, be relevant to the disease pattern in Ghana and align with the approved Selective List on Drugs, Medical Supplies and Equipment, with limited exceptions for emergencies
- Products must be approved by Ghana’s Food and Drugs Board (FDB), which typically requires advance registration
- Donated items must mirror those commonly used in Ghanaian healthcare settings
- Returned drugs, free samples and items issued to patients are not accepted
- A minimum one-year shelf life upon arrival is generally required
Failure to meet these requirements can result in delays, rejection or destruction of donated items.
Key Risks to Consider
Patient Safety Risks
- Reduced potency, degradation or unpredictable treatment effects
- Exposure to improper storage conditions
- Misalignment with local disease patterns, resistance profiles (e.g. antibiotics inconsistent with national stewardship protocols) or treatment guidelines
- Dosing, formulation or labeling inconsistencies
- Lack of continuity of care when donated therapies cannot be maintained locally
Operational and Logistical Risks
- Customs seizure or shipment delays
- Unexpected storage, disposal or destruction costs
- Mission disruptions and inefficiencies
Legal, Liability and Reputational Risks
- Potential negligence claims if patients are harmed
- Regulatory violations across U.S. and international jurisdictions
- Insurance policies that may not cover international clinical activity or donated products
- Perceived double standards if lower‑quality products are sent abroad
- Erosion of trust with mission partners and recipient communities
Equity, not convenience, should guide donation decisions. If a medication or supply is unsuitable for use domestically, it should not be considered acceptable elsewhere.
A More Responsible Path Forward
International medical donations can play a meaningful role in global health when they are carefully planned, compliant with regulations and aligned with local needs. In many cases, financial contributions or support through established humanitarian organizations offer a safer, more effective alternative. Thoughtful collaboration, risk awareness and regulatory diligence help ensure that generosity supports patients rather than exposing them to unintended harm. Connect with our team of Healthcare Risk Advisors to discuss all risk management solutions when planning for international medical donations.